Docetaxel for Breast Cancer Treatment-Side Effects on Ocular Surface, a Systematic Review

Abstract

Docetaxel is a very effective chemotherapeutic agent for the treatment of metastatic or locally advanced breast cancer. Epiphora (hyperlacrimation) has been shown to be the most common eye condition in patients receiving docetaxel-based chemotherapy. This symptom does not decrease visual acuity, but decreases the quality of life. Daily activities (reading, working on the computer, watching TV, and so on) are affected, with patients complaining about an alteration of daily life with the appearance of this symptom. The mechanism by which epiphora occurs is considered to be the canalicular stenosis, but the trials on the subject failed to reach statistical significance. The objective of this scoping review is to determine whether there is a treatment regimen-dependent relationship between docetaxel administration and the presence of epiphora in women with breast cancer. The inclusion criteria were met by 10 trials, from which one was excluded owing to data selection biases. Accordingly, nine studies were evaluated quantitatively and qualitatively in the present review. We included subjects with docetaxel as single treatment or docetaxel in combination with other chemotherapy compounds. The occurrence of epiphora among subjects treated with docetaxel, regardless of the therapeutic regimen used, was statistically significant (p = 0.005). The proportion of patients with epiphora after weekly administration of docetaxel (54 out of 131 subjects, 41.22%) was different compared with that of those who received docetaxel at three week intervals (112 out of 325 subjects, 34.15%), but the difference between the two was not statistically significant (p = 0.732). The present study demonstrates that epiphora occurs more frequently in patients receiving weekly docetaxel-based chemotherapy than those taking the three-weekly regimen, but the difference is not statistically significant. Ophthalmologic assessment of all patients starting this treatment is recommended. The causal relationship between canalicular stenosis and epiphora is not fully elucidated as long as this ocular symptom occurs in women who do not have stenosis of the lacrimal system. Further well-designed trials are required to bring new insights into the mechanisms of epiphora pathogenesis in subjects treated with docetaxel.

Harnessing Nanotechnology for Optimized Herbal Cancer Treatment: A Comprehensive Review of Nanoscale Drug Delivery Systems

“…DTX is a highly effective chemotherapy drug derived from plants and is used to treat various cancers, including breast cancer, head and neck cancer, stomach cancer, prostate cancer, and non-small-cell lung cancer. [122][123][124][125] However, commercial formulations of DTX have limited ability to cross the blood-brain barrier (BBB). Additionally, the use of DTX is restricted by its various side effects, such as nephrotoxicity, allergic reactions, decreased white blood cell count, neurotoxicity, and fluid retention.…”

Ocular adverse effects of anti-cancer chemotherapy

“…Several authors described the occurrence of narrowing and/or obstruction of the nasolacrimal canaliculus in breast cancer patients undergoing docetaxel treatment [18][19][20]. Additionally, studies have shown that epiphora (excessive tearing) is more prevalent in patients receiving weekly docetaxel treatment compared to those on a three-week treatment schedule [21,22].…”

Red Blood Cell Membrane-Camouflaged Polydopamine and Bioactive Glass Composite Nanoformulation for Combined Chemo/Chemodynamic/Photothermal Therapy

“…Notably, bioactive glass (BG) is commonly used in orthopedics and dentistry. It is chosen as a vehicle for drug delivery due to its excellent biocompatibility, bioactivity, and significant tumor growth inhibition properties. − Chemotherapy drugs, including nabumetone, paclitaxel, cyclophosphamide, docetaxel, epirubicin, paclitaxel analogues, and PARP inhibitors, are administered using the bionanosystem for breast cancer treatment. To develop novel therapeutic approaches, tubercidin (Tub), a well-known nucleoside, can undergo different metabolic reactions.…”